ABSTRACT The highly polymorphic system of serologically defined genetic markers on human IgG heavy chains (Gm allotypes) is second only to the HLA complex in terms of the large number of determinants, alleles, and haplotypes that can be used for analyses of disease associations and other genetic studies. However, present typing methods are based on the use of antiGm antisera that are derived mainly from fortuitously immunized human donors, often requiring processing before use, and must be used in a hemagglutination-inhibition assay that cannot be used in typing for isoallotypic determinants (currently termed "nonmarkers"). In studies presented here, we describe an allotyping system that utilizes monoclonal antibodies in a "sandwich" modification of the solid-phase radioimmunoassay, which is capable of reliable quantitative typing of allotypic, isoallotypic, and isotypic immunoglobulin determinants. We show that these highly reproducible, easily disseminated, and essentially inexhaustible reagents can be used for rapid, sensitive, and quantitative Gm typing. Using this system we define two previously unrecognized Gm determinants, one of which, found to date only in Caucasians, is different from all known Gm markers and thus defines previously unrecognized alleles and haplotypes. The other determinant cosegregates with the conventional G3m(bl) marker but is distinct from that marker on serological grounds. The successful preparation of mouse monoclonal antibodies that detect human Gm allotypic differences and the development of an assay system capable of typing isoallotypic as well as allotypic determinants opens the way to further dissection and application of this rich genetic system.
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Human immunoglobulin polymorphisms (Gm, Am, and Km allotypes) offer a broad range of serologically detectable markers for human genetic studies. The large number of alleles, particularly at the IgG1 and IgG3 loci, identify a series of geographically distributed immunoglobulin heavy chain (Igh) haplotypes that make the Igh region second only to HLA antigen in complexity (1, 2) . Recently a number of associations of certain diseases with particular Gm markers have been reported (3) (4) (5) (6) (7) (8) (9) (10) (11) . However, difficulties inherent in the current standard Gm typing methods limit the use of this genetic marker system.
Because the typing sera are mainly derived from fortuitously immunized human donors, they are relatively scarce and sometimes impossible to replace when consumed. Furthermore, except in a few cases (12, 13) , the characteristics of these reagents dictate their use in a hemagglutination-inhibition typing assay that depends on visual scoring and requires additional sources of human cells and "target" Rh antisera from a variety of donors (1) .
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Most of the antisera produced by inter-species immunizations have not been useful, principally because most genetic markers detected by these antibodies cannot be scored by the standard hemagglutination-inhibition assay. These antibodies, in fact, detect "isoallotypic" determinants that are polymorphic on one of the Ig isotypes (subclasses) in human sera but are monomorphic (always present) on other isotypes. Therefore, they can only be used to identify genetic differences between individuals when the polymorphic isotype is isolated from the serum samples prior to assay. Because this prohibits the typing of large numbers of samples by current methods, these determinants are now classified as "non-markers" and named accordingly-e.g., non-G3m(g) (1). Thus, a whole series of genetic markers have been inaccessible for lack of an appropriate assay system. Past attempts to develop radioimmunoassays (RIAs) have met with only variable success, primarily due to problems in purifying and radiolabeling antibodies from conventional antisera (12, 13) . The mouse monoclonal anti-Gm typing reagents and RIA typing methods described here signal an end to these difficulties. These reagents are essentially inexhaustible and can be broadly disseminated while the use of solid-phase RIA assays eliminates the need for additional cells and target antisera required in the hemagglutination-inhibition assay.
Furthermore, this technology allows "in-well" isolation of individual isotypes from serum samples and subsequent scoring for allotypic (or isoallotypic) determinants on the isolated isotype. Therefore, because non-markers and markers become operationally equivalent, these reagents and methods open the way for simplification of the current Gm notation and, more significantly, for exploitation of the full genetic potential of the Gm system by allowing individuals to be typed for the hitherto inaccessible isoallotypic determinants.
The (14, 15) . Antibody-producing hybrids were cloned using the fluorescence-activated cell sorter with previously described methods (16) . Monoclonal antibodies were purified from serum or ascites of hybridoma-injected mice by 50% ammonium sulfate precipitation and gel filtration chromatography (17) . The proteins were characterized by two-dimensional gel electrophoresis (18) . The production of antibody 3.18 (formerly named 18.1) has been described (19) . RIA (20) . The RIA competition assay for analysis of monoclonal antibody reactivity pattern was performed as described (19, 20) . Briefly, microtiter wells were coated with purified antibody. Graded amounts of highly purified, unlabeled myeloma proteins were then added to the well and followed immediately with a fixed amount of 1"I-labeled myeloma protein (20) .
RESULTS
The RIA reactivity patterns of the monoclonal anti-Gm antibodies shown in Table 1 terminants occur mainly, or perhaps exclusively, in Caucasian espectively. Samples were compared at sera dilutions that populations and represent the predominant allele(s) in these 00-3,000 cpm bound when tested with the anti-IgG3 (isopopulations (see Table 3 ). On the basis of the data we have coloclonal antibody C3. lected thus far, individuals from Oriental and African populations seldom (if ever) produce IgG3 molecules bearing the b6i typing with reagents such as the monoclonal antideterminant.
cussed above that detect isoallotypic determinants on Caucasianth rthermore, by using one of the anti-isotypic mono- In Caucasians, the IgG3 allele(s) that code for bi and b6i alibodies as the radiolabeled "second step," it allows so code for a series of other IgG3 allotypic determinants comneasurement of IgG3 serum levels. Thus, all samples monly referred to as the G3m b complex (bOblb3b4b5). Like idied at dilutions at which similar amounts of IgG3 bl, all of these latter determinants can be found in b6i-negative he anti-IgG3 plate-coat reagent, preventing differindividuals (see Table 3 ). Thus, b6i constitutes a unique Gm ;erum IgG3 levels from interfering with typing. lotypes. for Currently Known IgG3 Alleles. Data from >350
In our Caucasian sample there are about 69% bli, b6i-pos-I sera typed both with the monoclonal reagents (by itive, 2% bli-positive, b6i-negative, and 29% g positive, whereas tHemagglutination-inhibition typing with conventional anti-Gm allotype sera. Nearly all typing was confirmed by a restriction-site (DNA) polymorphism analysis that correlates strongly with Gm haplotypes (20) . no b6i-containing haplotypes occur in our Oriental or African samples. Thus, the b6i alleles seem to provide a sharp-distinction between bli alleles of differing ethnic origin, separating Caucasian from non-Caucasian bli-positive individuals. Despite the small Oriental and African samples, the difference from Caucasian is highly significant. DISCUSSION The two Gm determinants recognized by the monoclonal antibodies described here are prototypes of the classes of determinants that future interspecific monoclonal reagents can be expected to detect-that is, some reagents will detect determinants that substitute for currently known Gm markers, whereas others will detect previously unknown determinants. For example, the bli determinant (detected by the 3.40 and 3.41 reagents) is expressed concordantly with the classical bi determinant. Because bl is one of the most prevalent and well studied of the Gm determinants, this determinant provides a reference point that may facilitate transition to monoclonal-based RIA assays for Gm.
In contrast, the b6i determinant (detected by the 3.18 antibody) is distinct from any known G3m determinant and reveals a new level of complexity among Gm haplotypes. It is found only in individuals that express the G3m b complex of determinants; however, it is not found in all such individuals. As we have shown, IgG3 allele(s) that code for the G3m b complex in conjunction with b6i predominate in Caucasian populations but are absent (or are very rare) in Oriental and African populations. Thus, in addition to defining previously unrecognized IgG3 allele(s) and Gm haplotype(s), this determinant defines a previously unrecognized split among the G3m b complex-positive individuals in Caucasian populations and distinguishes the IgG3 allele(s) expressed in the majority of such individuals from the allele(s) expressed in Oriental and African populations and in a small minority of Caucasians.
Curiously, the b6i determinant is highly conserved throughout vertebrate evolution and occurs in reptiles, Aves, and mammals (19) ; however, its representation on immunoglobulins varies considerably. In the human, it is present as an isoallotypic determinant polymorphic on IgG3, is monomorphic on IgG2, and is absent on other isotypes. In contrast, in the mouse it is present as a simple allotypic determinant that distinguishes the Igh4a and Igh-4b allotypes on IgG1 (22) . In fact, the 3.18 antibody that detects this determinant was derived from a mouse alloimmunization (unlike the 3.40 and 3.41 monoclonal reagents) and was isolated originally because it identified the mouse allotypic difference.
We have had to break with the established World Health Organization notation for human immunoglobulins (23) in naming the isoallotypic Gm determinants identified here. The World Health Organization notation defines isoallotypic determinants as non-markers and requires placement of the prefix "non-" before the determinant name. This prefix is clearly inappropriate for determinants that, as we have shown, constitute perfectly valid genetic markers when used with an appropriate (RISA) assay. Thus, we have provisionally named the previously unrecognized determinants in accord with the World Health Organization notation for allotypic Gm markers and have added the suffix "i" to indicate that the determinant is isoallotypici.e., bli and b6i.
In summary, the data we have presented define previously Genetics: Zelaschi et aL Proc. Natl. Acad. Sci. USA 80 (1983) unrecognized Gm determinants, alleles, and haplotypes. These will help us to understand the origins of the immunoglobulin genes in human populations. On a technical level, these findings demonstrate conclusively that the mouse is capable of producing the kinds of monoclonal reagents needed for Gm typing. Thus, they open the way for development of a bank of monoclonal anti-allotype reagents that should complement and, in some cases, replace conventional anti-Gm antisera. Further, the RISA typing assay we describe (or perhaps an equivalent enzyme-linked immunosorbent typing assay) introduces the capability for easy typing of (formerly inaccessible) isoallotypic as well as allotypic determinants from whole human sera. These easily disseminated and essentially inexhaustible monoclonal reagents provide the potential for widespread and easier investigations of human immunoglobulin and related polymorphisms.
